Drugs / recombinant vaccinia virus
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00116597 | Nov 2002 → Jul 2007 | melanoma | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant vaccinia virus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00116597 ↗ |
| Known as | rVV | “We used a rVV encoding gp100(280-288), Melan-A/MART-1(27-35) and tyrosinase(1-9) HLA-A0201 restricted epitopes and CD80 and CD86 costimulatory molecules in stage III and IV...” PMID 19935776 ↗ Nov 2009 |
| Route | Other | “The patients are immunized intranodally (groin lymph node) under ultrasonographic guidance” NCT00116597 ↗ |